You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 HOME Hepatitis C Hepatitis B HIV and AIDS HIV-HCV Coinfection HIV-HBV Coinfection About Us
 HIV and Hepatitis.com Coverage of the
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009)
 July 19 - 22, 2009, Cape Town, South Africa
 The material posted on HIV and Hepatitis.com about IAS 2009 is not approved by nor is it a part of IAS 2009.
Once Daily Darunavir/ritonavir: Experience in a Single Centre

Darunavir (DRV; Prezista) is a protease inhibitor (PI) with activity against wild type and protease inhibitor-resistant HIV when boosted with low dose ritonavir. In a presentation IAS 2009, investigators describe their experience of using once daily darunavir/ritonavir within the Chelsea & Westminster Hospital cohort. According to the authors, in this cohort of treatment-naïve and experienced patients with no background PI resistance, once daily darunavir/ritonavir (900/100mg) demonstrated effective virological suppression and was well tolerated.

Poster

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




 Google Custom Search











 
HIV and Hepatitis.com